On Thursday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), added 0.47% and closed at $55.05 in the last trading session. The last trading range of the stock ranges between $54.48 and $55.36. Bristol-Myers Squibb Company (BMY) recently declared new data across eight tumor types evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), as monotherapy or in combination, in addition to new assets, to be presented at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen, Denmark from October 7–11. Data presented at this congress underscore the Company’s commitment to its portfolio and to discover the next wave of transformational Immuno-Oncology medicines, counting combination therapies, for difficult-to-treat cancers.
“Bristol-Myers Squibb continues to lead the scientific understanding of Immuno-Oncology with an extensive portfolio and a differentiated clinical development program where we have set a high bar of success to look for clear and differentiated improvements over presently available therapies,” said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. “We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to assist even more patients with cancer.”
EnteroMedics Inc (NASDAQ:ETRM), dropped -1.22% and closed at $0.130 in the last trading session. The last trading range of the stock ranges between $0.12 and $0.14. The company’s Market capitalization is $9.53 Billion with the total Outstanding Shares of 69.70 million. EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, recently declared that vBloc® Neurometabolic Therapy is now available to U.S. veterans at U.S. Department of Veterans Affairs (VA) medical facilities. This is made possible through the formerly-declared EnteroMedics partnership with Academy Medical, LLC, a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense (DoD) facilities. As of October 1, 2016, vBloc was added to Academy Medical’s five year sole source agreement with the U.S. Department of Veterans Affairs that allows any VA surgeon in the U.S. to purchase the vBloc System from Academy Medical under a national contract.
“VA surgeons across the U.S. now have access to a safe and effective treatment option for obesity,” said Sachin Kukreja, M.D., Director, Bariatric Surgery, VA North Texas Health Care System. “Our center has extensive experience and success with vBloc Therapy and we look forward to expanding the reach of this exciting new treatment to eligible obese patients who do not wish to undergo anatomy-altering, restrictive surgeries.”
“We are very happy that VA surgeons now have the ability to treat over one million eligible veterans fighting obesity with vBloc Therapy,” said Dan Gladney, EnteroMedics’ President and Chief Executive Officer. “The veterans of our armed services, in addition to all patients, deserve access to every option that may assist in their battle against obesity. We look forward to working closely with the VA and Academy Medical to train VA surgeons so they are prepared to offer vBloc Therapy and perform implants as soon as possible.”
Blackstone Group LP (NYSE:BX), lost -1.39% and closed at $24.79 in the last trading session. The last trading range of the stock ranges between $24.65 and $25.14. During the 52-week trading session the minimum price at which share price traded, registered at $22.31 and reached to max level of $35.24. Optiv Security, a market-leading provider of end-to-end cyber security solutions, recently declared that it has received two Palo Alto Networks® NextWave 2016 awards: Professional Services Partner of the Year for the Americas and Excellence in Support for the Americas. During the recent Palo Alto Networks Sales Kickoff event in Nashville, Tennessee, Optiv was recognized for its extensive cyber security expertise and ability to deliver innovative solutions that meet the evolving security needs of global organizations.
This is the seventh successive year that Optiv has been recognized as a top Palo Alto Networks NextWave channel partner.
“It is critical for us to work closely with partners that have the right expertise and experience with our Next-Generation Security Platform to ensure we are providing the highest quality product and service to our customers,” said Todd Palmer, vice president of Americas Channel Sales, Palo Alto Networks. “Optiv has proven to be a trusted partner with a commitment to training certified experts to deliver our solutions, and we are thrilled to recognize their exceptional services offerings and capabilities.”